Back to search

Article

Small molecule v-ATPase inhibitor Etidronate lowers levels of ALS protein ataxin-2

2021-12-21

Abstract excerpt

<h4>Summary</h4> Antisense oligonucleotide therapy targeting ATXN2 —a gene in which mutations cause neurodegenerative diseases spinocerebellar ataxia type 2 and amyotrophic lateral sclerosis—has entered clinical trials in humans. Additional methods to lower ataxin-2 levels would be beneficial not only in uncovering potentially cheaper or less invasive therapies, but also in gaining greater mechanistic insight in...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
71715a8d-a6df-5bd7-87a8-53419ea8bb3c
DOI
10.1101/2021.12.20.473567
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Small molecule v-ATPase inhibitor Etidronate lowers levels of ALS protein ataxin-2DOI 10.1101/2021.12.20.473567
Select a neighboring publication to make it the new centre.